Brief Summary
To assess the freedom from local failure at 12 months after Stereotactic Body Radiotherapy (SBRT). Also to assess the safety, efficacy and feasibility of SBRT in the treatment of high riskthe possibility that something bad will happen localisedaffecting only one area of body pancreatic cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs.
Intervention / Treatment
- Radiation: Stereotactic Body Radiotherapy (SBRT)
Inclusion Criteria
- Age ≥ 18 and able to give informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment.
- Patients with histologically or cytologically confirmed locally advancedat a late stage, far along adenocarcinomacancer arising from mucus-producing glands in organs of the pancreasa long, flat organ that sits between the stomach and the spine that plays a key role in digestion and blood sugar regulation, including patients with extrapancreatic extension (Stage IIA), nodea small lump or mass of tissue in your body positive (Stage IIB), borderline resectable or locally advanced as defined by AGITG guidelines
- ECOG performance status 0-1
- Measurable disease as defined by RECIST 1.1
- Have received or plan to receive chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells
- Successful insertion of fiducial markers